Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will release its third quarter 2022 results and corporate update on November 15, 2022, followed by a conference call at 8:30 a.m. EST / 14:30 CET. Investors can join via phone or through a webcast available on the company’s website. The call features the latest updates on Affimed’s immuno-oncology initiatives and its ROCK^® platform designed to combat various cancers by utilizing the innate immune system. A replay will be accessible for 30 days post-call.

Positive

• Affimed's proprietary ROCK® platform enables targeted tumor recognition and elimination.
• Affimed is the first company with a clinical-stage ICE®.

Negative

• None.

HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2022 results and corporate update on Tuesday, November 15, 2022. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.

The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://register.vevent.com/register/BI62ec6e16028b424eba578af8c49e4240, and you will be provided with dial-in details and a pin number.

Note: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.

A replay of the webcast will be accessible at the same link for 30 days following the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed release its Q3 2022 results?

Affimed will release its Q3 2022 results on November 15, 2022.

What is the purpose of the upcoming Affimed conference call?

The conference call will provide an update on Affimed’s third quarter results and corporate activities.

What time is the Affimed conference call scheduled for?

The conference call is set for 8:30 a.m. EST / 14:30 CET.

How can I access the Affimed conference call?

The conference call can be accessed via phone or through a live webcast available on Affimed's website.

How long will the webcast replay of the Affimed call be available?

The replay of the webcast will be available for 30 days after the call.